Interaction of Model Aryl- and Alkyl-Boronic Acids and 1,2-Diols in Aqueous Solution

Journal of Pharmaceutical Sciences

Volumn 104, Issue 4, 2015, Pages 1399-1408

  Marinaro, William A ^a   Prankerd, Richard ^b   Kinnari, Kaisa ^a   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

1,2 diols,; acid base equilibria; boronic acid; esters; isothermal calorimetry; mannitol; stability; structure property relationship (SPR)

Indexed keywords

1,2 DIOL DERIVATIVE; ALKYL GROUP; AROMATIC COMPOUND; ARYL BORONIC ACID; BORON; BORONIC ACID DERIVATIVE; ESTER; ESTER DERIVATIVE; LEWIS ACID; MANNITOL; POLYOL; SORBITOL; UNCLASSIFIED DRUG; ALCOHOL DERIVATIVE; SOLUTION AND SOLUBILITY;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; ENTHALPY; ENTROPY; EQUILIBRIUM CONSTANT; IONIC STRENGTH; ISOMER; ISOTHERMAL TITRATION CALORIMETRY; MICROCALORIMETRY; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; POTENTIOMETRIC TITRATION; QUANTITATIVE STUDY; STEREOCHEMISTRY; TITRIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY; CALORIMETRY; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG STABILITY; ESTERIFICATION; KINETICS; MEDICINAL CHEMISTRY; OSMOLARITY; PHARMACEUTICS; POTENTIOMETRY; PROCEDURES; SOLUTION AND SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALCOHOLS; BORONIC ACIDS; CALORIMETRY; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; ESTERIFICATION; ESTERS; KINETICS; LEWIS ACIDS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OSMOLAR CONCENTRATION; PHARMACEUTICAL SOLUTIONS; POTENTIOMETRY; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 84924803322     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24346     Document Type: Article

References (23)

1. Millennium Pharmaceuticals, Inc. 2004. VELCADE® (bortezomib) for injection - Prescribing information. Rev 1 ed., Cambridge, Massachusetts.
2. Yoshino K, Suzuki A, Mori Y, Kakihana H, Honda C, Mishima Y, Kobayashi T, Kanda K. 1989. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol 165:127-129.
3. Plamondon L, Grenier L, Adams J, Gupta S. 2006. Formulation of boronic acid compounds. Patent US 7109323 B2.
4. Gupta SL, Stella VJ, Waugh W. 2005. Formulation of boronic acid compounds. Patent US6958319.
5. Gupta SL, Stella VJ, Waugh W. 2005. Formulation of boronic acid compounds. Patent US6713446 B2.
6. Wu S, Waugh W, Stella VJ. 2000. Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B (OH) 2. J Pharm Sci 89:758-765.
7. Byrn SR, Tishmack PA, Milton MJ, van de Velde H. 2011. Analysis of two commercially available bortezomib products: Differences in assay active agent and impurity profile. AAPS Pharm Sci Tech 12:461-467.
8. Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Paggliuca R, Ottiero M, Scalfaro M, Rotoli B. 2009. An NMR study of the bortezomib degradation under clinical use conditions. Adv Hematol 2009:1-5.
9. Yang W, Gao X, Wang B. 2003. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23:346-368.
10. Yan J, Springsteen G, Deeter S, Wang B. 2004. The relationship among pKa, pH, and binding constants in the interactions between boronic acids and diols - It is not as simple as it appears. Tetrahedron 60:11205-11209.
11. Springsteen G, Wang B. 2002. A detailed examination of boronic acid-diol complexation. Tetrahedron 58:5291-5300.
12. Martínez-Aguirre MA, Villamil-Ramos R, Guerrero-Alvarez JA, Yatsimirsky AK. 2013. Substituent effects and pH profiles for stability constants of arylboronic acid diol esters. J Org Chem 78:4674-4684.
13. 13C NMR evidence for the β-D-fructofuranose 2, 3, 6-(p-phenylalanylorthoboronate) structure. J Pharm Sci 89:215-222.
14. Islam TM, Yoshino K, Sasane, A. 2003. 11B NMR study of p-carboxybenzeneboronic acid ions for complex formation with some monosaccharides. Anal Sci 19:455-460.
15. Schmidt E, Dooley N, Ford SJ, Elliott M, Halbert GW. 2012. Physicochemical investigation of the influence of saccharide-based parenteral formulation excipients on L-p-boronphenylalanine solubilisation for boron neutron capture therapy. J Pharm Sci 101:223-232.
16. Iwatsuki S, Nakajima S, Inamo M, Takagi HD, Ishihara K. 2007. Which is reactive in alkaline solution, boronate ion or boronic acid? Kinetic evidence for reactive trigonal boronic acid in an alkaline solution. Inorg Chem 46:354-356.
17. Sugihara JM, Bowman CM. 1958. Cyclic benzeneboronate esters. J Am Chem Soc 80:2443-2446.
18. Perun TJ, Martin JR, Egan RS. 1974. Cyclic phenylboronates as hydroxyl protecting groups in the synthesis of monoesters of macrolide aglycones. J Org Chem 39:1490-1493.
19. Jager J, Graafland T, Schenk H, Kirby AJ, Engberts JBFN. 1984. Intramolecular-catalyzed sulfonamide hydrolysis. VII. The Thorpe- Ingold effect in the intramolecular carboxyl-catalyzed hydrolysis of sulfonamides. J Amer Chem Soc 106:139-143.
20. Davey AE, Parsons AF, Taylor RJK. 1989. Reactions of dithiane derived alcohols: Promotion of the Thorpe-Ingold effect by trimethylsilyl and tert-butyl substituents. J Chem Soc Perkin Trans I 10:1853-1858.
21. McIntyre S, Sansbury FH, Warren S. 1991. The Thorpe-Ingold effect in the synthesis of tetrahydro-furans and pyrans by competitive cyclization with phenylthio migration. Tetra Let 32:5409-5412.
22. Forbes MDE, Patton JT, Myers TL, Maynard HD, Smith DW Jr, Schulz GR, Wagener KB. 1992. Solvent-free cyclization of linear dienes using olefin metathesis and the Thorpe-Ingold effect. J Amer Chem Soc 114:10978-10980.
23. Yoshino K, Kotaka M, Okamoto M, Kakihana H. 1979. Boron-11 NMR study of the complex formation of borate with catechol and L-dopa. Bull Chem Soc Japan 52:3005-3009.